Please use this identifier to cite or link to this item:
Title: Following the results of the EMPA-REG OUTCOME trial with Empagliflozin, is it possible to speak of a class effect?
Author: Ampudia-Blasco, Francisco Javier
Romera, Irene
Ariño, Bernat
Gomis, Ramon, 1946-
Keywords: Malalties cardiovasculars
Cardiovascular diseases
Issue Date: 13-Jan-2017
Abstract: The recently published cardiovascular outcomes data for the first sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, have shown cardiovascular safety and additional benefits in patients with type 2 diabetes and established cardiovascular disease. Empagliflozin showed lower rates of death from cardiovascular causes or from any causes and lower hospitalization rates from heart failure compared with placebo, both in addition to standard care. This commentary discusses the existence of a possible class effect considering the available evidence described for other SGLT2 inhibitors.
It is part of: International Journal of General Medicine, 2017, vol. 10, p. 23-26
Related resource:
ISSN: 1178-7074
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
669654.pdf112.02 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons